Comparative Pharmacology
Head-to-head clinical analysis: CAPITAL AND CODEINE versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPITAL AND CODEINE versus QOLIANA.
CAPITAL AND CODEINE vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist, producing analgesia and CNS depression. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
Acetaminophen 300 mg plus codeine phosphate 30 mg orally every 4 hours as needed for pain; maximum acetaminophen 3000 mg/day, codeine 180 mg/day.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Codeine: 2.5-3 hours; Codeine-6-glucuronide: 2.5-3 hours; Morphine: 1.5-4.5 hours. Clinical context: In poor CYP2D6 metabolizers, half-life may be prolonged due to reduced clearance.
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal: 90% (codeine and metabolites, primarily as codeine-6-glucuronide and norcodeine), Biliary/Fecal: <10%
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist